| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on November 13, 2007
Accepted on January 7, 2008
Institute of Anatomy, University of Duisburg-Essen, Essen, Germany; Department of Obstetrics and Gynaecology, University of Duisburg-Essen, Essen, Germany
* To whom correspondence should be addressed. E-mail: isabella.gashaw{at}uk-essen.de.
The pro-angiogenic factor CYR61 (CCN1) mediates different signals in tumorigenesis, angiogenesis and is involved in the pathogenesis of endometriosis. In this study, we investigated the temporal and spatial expression pattern in human endometrium during the menstrual cycle and its possible regulation mechanisms in the pre-menstrual phase. CYR61 transcript expression showed two distinct periods of elevated levels in the proliferative phase and in menstrual effluents. Since the menstrual breakdown of the functionalis is triggered by cytokines, prostaglandins as well as hypoxia, we employed a benign endometrial cell line to investigate if CYR61 is regulated by these factors. Hypoxic conditions transiently induced CYR61 mRNA levels and enhanced the secretion of the CYR61 protein into the medium. The hypoxia inducible factor HIF1
mediated this effect on CYR61 as evidenced by dimethyloxalylglycine treatment and by HIF1
siRNA. CYR61 mRNA expression was further regulated by IL1, TNF
, PGE2 and PGF2
. In addition, TNF
and PGE2 elevated significantly CYR61 cellular protein levels in well oxygenated cells but had only a slight effect on the quantity of secreted protein. Moreover, PGE2 combined with hypoxic conditions increased CYR61 mRNA and protein levels synergistically whereas the combination with TNF
abolished the CYR61 levels induced by hypoxia.
Taken together the upregulation of CYR61 by hypoxia via HIF1
, TNF
and PGE2 could represent possible mechanisms for the CYR61 increase at the onset of menstruation. The opposite effect of TNF
combined with hypoxia on CYR61 upregulation could contribute to a balanced expression level of this angiogenic factor in the endometrium.
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |